Furthermore, hyperactivation of TGFβ signaling in advanced-stage malignant tumors also swiftly decreases efficacy of ICI therapy in the TME (106), whereas malignant tissue insensitive to ICI treatment exhibits a high expression pattern of TGFβ1 (107). The gene discussed is TGFB1; the disease is cancer.